Aerie Pharmaceuticals traded at $11.09 this Thursday August 11th, decreasing $0.55 or 4.73 percent since the previous trading session. Looking back, over the last four weeks, Aerie Pharmaceuticals lost 34.91 percent. Over the last 12 months, its price fell by 24.15 percent. Looking ahead, we forecast Aerie Pharmaceuticals to be priced at 8.66 by the end of this quarter and at 7.96 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Aerie Pharmaceuticals 11.09 -0.55 -4.73% -24.15%
Alimera Sciences 6.77 -0.15 -2.17% -20.35%
Amarin 1.69 0.08 4.66% -68.91%
Bluebird Bio 6.31 0.38 6.41% -66.49%
Cara Therapeutics 11.64 0.01 0.09% -12.68%
Coherus Biosciences 12.86 0.21 1.66% -5.65%
Endo International 0.38 -0.02 -4.16% -90.34%
Horizon Pharma 66.97 -0.13 -0.19% -37.29%
Insmed 27.11 0.36 1.35% 13.34%
Jazz Pharmaceuticals 154.25 -3.18 -2.02% 5.90%
Merck & Co 89.58 0.65 0.73% 16.76%
Mirati Therapeutics 83.00 2.55 3.17% -40.83%
Novartis 80.09 -0.95 -1.17% -6.83%
Iveric bio Inc. 13.54 0.51 3.91% 42.68%
Pacira 56.34 0.08 0.14% -3.41%
Regeneron Pharmaceuticals 626.71 2.81 0.45% 0.31%
Revance Therapeutics 22.69 1.25 5.83% -13.36%
Supernus Pharmaceuticals 31.57 0.31 0.99% 27.61%
Teva Pharmaceutical Industries 11.27 0.18 1.62% 12.81%
Bausch Health Companies Inc 7.87 -0.05 -0.63% -77.16%
Zoetis 173.05 -0.13 -0.08% -14.11%

Indexes Price Day Year
USND 12879 98.70 0.77% -13.12%
US2000 1988 12.46 0.63% -10.59%

Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. The Company’s commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa is under preclinical and clinical trials. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma. Rocklatan is under preclinical and clinical trials to be effective in reducing IOP.